Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades …